Q3 Earnings Estimate for MMSI Issued By Barrington Research

Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) - Research analysts at Barrington Research dropped their Q3 2025 earnings per share estimates for shares of Merit Medical Systems in a research note issued to investors on Wednesday, February 26th. Barrington Research analyst M. Petusky now forecasts that the medical instruments supplier will post earnings of $0.93 per share for the quarter, down from their prior estimate of $0.96. Barrington Research currently has a "Outperform" rating and a $111.00 target price on the stock. The consensus estimate for Merit Medical Systems' current full-year earnings is $3.37 per share. Barrington Research also issued estimates for Merit Medical Systems' FY2025 earnings at $3.70 EPS and FY2026 earnings at $4.00 EPS.

Several other brokerages also recently commented on MMSI. Piper Sandler reaffirmed an "overweight" rating and issued a $116.00 target price (up from $114.00) on shares of Merit Medical Systems in a research note on Wednesday, January 29th. Wells Fargo & Company decreased their price objective on shares of Merit Medical Systems from $120.00 to $117.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Needham & Company LLC dropped their target price on shares of Merit Medical Systems from $122.00 to $116.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. Canaccord Genuity Group cut their target price on Merit Medical Systems from $128.00 to $127.00 and set a "buy" rating on the stock in a research note on Wednesday, February 26th. Finally, Raymond James upped their price target on Merit Medical Systems from $105.00 to $110.00 and gave the company an "outperform" rating in a research report on Tuesday, December 31st. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $110.78.

Remove Ads

Merit Medical Systems Trading Down 3.0 %

MMSI stock traded down $3.12 during midday trading on Monday, hitting $101.73. The company had a trading volume of 607,047 shares, compared to its average volume of 582,915. The stock has a market cap of $5.99 billion, a price-to-earnings ratio of 49.87, a PEG ratio of 2.34 and a beta of 0.87. Merit Medical Systems has a 52 week low of $70.70 and a 52 week high of $111.45. The company has a current ratio of 5.36, a quick ratio of 3.82 and a debt-to-equity ratio of 0.57. The stock's 50 day moving average price is $103.29 and its 200 day moving average price is $100.30.

Institutional Investors Weigh In On Merit Medical Systems

Hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in shares of Merit Medical Systems by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 6,648,659 shares of the medical instruments supplier's stock valued at $643,058,000 after purchasing an additional 63,314 shares during the last quarter. State Street Corp increased its position in Merit Medical Systems by 0.7% during the 3rd quarter. State Street Corp now owns 2,231,701 shares of the medical instruments supplier's stock valued at $220,559,000 after buying an additional 15,098 shares in the last quarter. FMR LLC raised its stake in Merit Medical Systems by 31.6% during the fourth quarter. FMR LLC now owns 2,076,439 shares of the medical instruments supplier's stock valued at $200,833,000 after buying an additional 499,193 shares during the last quarter. Fuller & Thaler Asset Management Inc. boosted its holdings in Merit Medical Systems by 2.3% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 1,633,246 shares of the medical instruments supplier's stock worth $157,968,000 after acquiring an additional 36,489 shares in the last quarter. Finally, Invesco Ltd. grew its stake in shares of Merit Medical Systems by 8.3% in the fourth quarter. Invesco Ltd. now owns 1,535,468 shares of the medical instruments supplier's stock worth $148,510,000 after acquiring an additional 118,142 shares during the last quarter. Institutional investors own 99.66% of the company's stock.

Insider Transactions at Merit Medical Systems

In other news, insider Brian G. Lloyd sold 25,000 shares of the business's stock in a transaction on Friday, February 28th. The shares were sold at an average price of $99.50, for a total transaction of $2,487,500.00. Following the sale, the insider now owns 38,993 shares in the company, valued at approximately $3,879,803.50. The trade was a 39.07 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Raul Jr. Parra sold 12,451 shares of the company's stock in a transaction dated Friday, February 28th. The stock was sold at an average price of $98.81, for a total transaction of $1,230,283.31. Following the completion of the sale, the chief financial officer now directly owns 24,201 shares in the company, valued at $2,391,300.81. This represents a 33.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 109,132 shares of company stock valued at $11,139,521. Corporate insiders own 3.70% of the company's stock.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.